African Americans have a 3-5-fold increased risk of developing chronic kidney disease (CKD) and end-stage renal disease (ESRD) 1,2 . Recent studies indicate that coding-region variants (G1 and G2) in the apolipoprotein L1 (APOL1) gene explain much of this excess risk 3, 4 . APOL1 variants contribute to about 70% of nondiabetic ESRD (up to 40% of all ESRD) in African Americans, and they are associated with focal segmental glomerulosclerosis (FSGS), hypertension-attributed ESRD and HIV-associated nephropathy (HIVAN) 5 . Unlike most diseaseassociated high-penetrant variants, the G1 and G2 alleles are present in the general population with a relatively high allele frequency [6] [7] [8] . It seems that these variants emerged as a result of positive selection, given that they protect against African sleeping sickness, a disorder caused by the parasite Trypanosoma brucei rhodesiense 8 . APOL1 functions as a component of the trypanolytic factor. It is taken up by the parasite, where it incorporates into endosomal membranes and transits to the lysosome. The low lysosomal pH induces a conformational change in the protein, and it forms a pore-forming channel. The resulting ion transport causes osmotic lysosomal swelling and parasite death.
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The reference (G0) APOL1 variant has lost its trypanolytic function in T. brucei rhodesiense owing to the emergence of a trypanosomal protein (serum-resistance associated (SRA)) that binds to and neutralizes the activity of APOL1 protein 9 . APOL1 risk variants (G1 and G2) have a decreased affinity for SRA and are able to lyse T. brucei rhodesiense subspecies 4 .
Surprisingly, even 7 years after the discovery of this genetic association, little is known about the functional role of APOL1 variants in kidney-disease development. Proof-of-concept experiments using animal models to demonstrate that APOL1 G1 (double missense mutations) and G2 (an indel) variants are causal mutations for kidney disease are lacking, and indeed, some recent studies failed to recapitulate kidney disease in animals expressing one of these risk alleles 10 . A key barrier is that mice and other model organisms lack the APOL1 gene. In humans, APOL1 expression does not show tissue specificity, which makes it difficult to identify the cell type critical to renal-disease development 11 . Furthermore, the variant is seemingly associated with diverse clinical phenotypes, including hypertensive a r t i c l e s 4 3 0 VOLUME 23 | NUMBER 4 | APRIL 2017 nature medicine nephrosclerosis, FSGS, HIVAN and lupus nephritis 12 . Recent pathological studies indicate increased incidence of solidified-type global sclerosis in individuals with high-risk APOL1 genotypes as compared to people with kidney disease who carry the reference allele [13] [14] [15] . Observational cohort studies show that individuals with a high-risk genotype have higher albuminuria and faster GFR decline [16] [17] [18] . The goal of this study was to answer the question of whether kidney-specific expression of the APOL1-G1 and APOL1-G2 risk variants causes kidney disease. To address this issue, we generated a new mouse model with conditional and inducible expression of APOL1 reference and risk alleles. We found that podocyte-specific expression of APOL1 risk alleles, but not of the G0 allele, causes severe albuminuria and glomerulosclerosis. We show that this model recapitulates features of the human phenotype at the functional, structural and molecular levels, indicating that the G1 and G2 variants are disease-causing alleles. On the mechanistic level, we show that APOL1 mostly resides in the late endosomal compartment, and that when compared to the reference allele, expression of its risk variants
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Nphs1-rtTA TRE-APOL1-G0 of Nphs1-rtTA/TRE-APOL1-G0 (n = 11), Nphs1-rtTA/TRE-APOL1-G1 (n = 11), Nphs1-rtTA/TRE-APOL1-G2 (n = 12) mice. Single transgenic littermates served as controls (ctl) (n = 8, 6, 6 for G0, G1 and G2, respectively). Statistics were calculated by Student's t-test, *P = 0.0154 (G0 versus G1), P = 0.0077 (G0 versus G2). (c) Serum blood urea nitrogen (BUN) and creatinine levels of control (CTL) (n = 6) and Nphs1-rtTA/TRE-APOL1-G2 (n = 4) mice on doxycycline diet for 12-19 d. Student's t -test, *P = 0.0042 (BUN), P = 0.0279 (creatinine). The data are presented as means ± s.d. (d) Representative PAS-stained kidney images of Nphs1-rtTA/TRE-APOL1-G0, Nphs1-rtTA/TRE-APOL1-G1 and Nphs1-rtTA/TRE-APOL1-G2 mice. Bottom, higher-magnification images of the boxed regions in the top images (n > 5 per line). Scale bars, 20 µm (top); 10 µm (bottom).
(e) Quantification of the histological findings of Nphs1-rtTA/TRE-APOL1-G0 (n = 12), Nphs1-rtTA/TRE-APOL1-G1 (n = 12), Nphs1-rtTA/TRE-APOL1-G2 (n = 7) mice. Student's t-test, P = 0.0087 (G0 versus G1), *P = 0.0048 (G0 versus G2). (f) Representative transmission electron micrographs (TEM) of Nphs1-rtTA/TRE-APOL1-G0/G1/G2 mice (n = 26, 74, 54 for G0, G1, G2 mice, respectively). Scale bars, 500 nm. (g) Differentially expressed pathways by RNA-sequencing identified using gene-set enrichment analysis. Y axis, log (P) of the false-discovery rate (FWER, family-wise error rate).
(h) Heat-map analysis of mouse orthologs of Ubd, Cxcl9, Cxcl1 and Muc13, previously reported to be differentially expressed in individuals with high-risk versus low-risk APOL1 allele nephrotic syndrome. Red, high transcript levels; green, low transcript levels.
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leads to altered vesicular trafficking, decreased autophagic flux and shifting of cells to an inflammatory-death pathway.
RESULTS
Podocyte-specific expression of G1 or G2 APOL1 in mice leads to kidney disease We used the doxycycline-inducible (rtTA) system (Fig. 1a) to generate mice with podocyte-specific, conditionally inducible APOL1 expression. Using this transgenic system, we expressed GFP and either the G0 reference allele or one of the two risk alleles (G1 or G2) (Supplementary Fig. 1 ) from a bicistronic promoter (TRE-GFP/APOL1). We used the nephrin (Nphs1) promoter to drive podocyte-specific rtTA expression. Successful transgene expression following doxycycline administration was confirmed by immunohistochemistry (Fig. 1a) . We identified at least three founders from each transgenic line that produced offspring expressing APOL1 and GFP transcripts and proteins. Male littermates of these founders were used for all further analysis. Double-transgenic mice (Nphs1-rtTA/ TRE-APOL1) are called transgenic mice and single-transgenic mice (TRE-APOL1) are controls.
Littermates of double-and single-transgenic mice were placed on a doxycycline diet at 3.5 weeks of age. Transgenic mice with either risk allele (Nphs1-rtTA/TRE-APOL1-G1 and Nphs1-rtTA/TRE-APOL1-G2) had a significantly higher mean urinary-albumin-to-creatinine ratio (ACR) as compared to transgenic mice expressing the reference allele (Nphs1-rtTA/TRE-APOL1-G0) (Fig. 1b) . Kidney functional analysis, including measurements of serum blood urea nitrogen (BUN) and serum creatinine, showed that mice expressing the G2 risk allele had significant azotemia as compared to control (wild-type) mice (Fig. 1c) . The azotemia probably contributed to the greater mortality rate observed in mice expressing the G2 risk allele as compared to those expressing the reference (G0) allele (Supplementary Fig. 2a) .
Structural examination performed by light-microscopy analysis of periodic acid-Schiff (PAS)-stained kidney sections indicated increased global and segmental glomerulosclerosis in mice expressing either APOL1 risk allele (Fig. 1d) . By 3 weeks after doxycycline induction, transgenic mice carrying the G1 or G2 allele developed severe (solidified-type) global and segmental sclerosis as compared to G0 control mice (Fig. 1e) . Ultrastructural analysis using transmission a r t i c l e s electron microscopy (TEM) showed increased foot-process effacement-an important ultrastructural characteristic of proteinuric glomerulopathies in patients-in mice expressing a risk allele as compared to those expressing the reference allele (Fig. 1f) .
Next, we performed molecular analysis by performing RNA-seq of whole-kidney lysates from control, reference-allele and riskallele-expressing mice (Supplementary Fig. 2b ). This unbiased analysis identified many differentially expressed genes (Supplementary Table 1 ). We used gene-set enrichment analysis to identify key pathways driving these transcriptional changes (Fig. 1g) . The top differentially expressed pathways included JAK-STAT signaling, cytokine-cytokinereceptor interaction and phagosome-related genes, and thus indicated a potential connection between APOL1-associated kidney disease and immunity 19 (Fig. 1g, Supplementary Fig. 2c and Supplementary Table 2). We have also examined the expression of five genes reported to be differentially expressed in patients with nephrotic syndrome with low-or high-risk APOL1 allele status 20 . Except for one humanspecific gene (SNORA14), all four genes that are present in mice showed increased expression in the risk-variant mouse model as compared to reference-allele mice ( Fig. 1h) and showed statistical correlation with the degree of glomerulosclerosis (Supplementary Table 3 ).
G1-and G2-APOL1-induced phenotypes are cell-type and dose dependent
To show that the renal-phenotype development after induced expression of G1 or G2 is not due to nonspecific toxicity, we generated mice with tubule-specific expression of APOL1 by crossing the TRE-APOL1 transgenic mice with paired-box 8 (Pax8)-rtTA mice. We confirmed transgene expression in the Pax8-rtTA/TRE-APOL1-G0 and Pax8-rtTA/TRE-APOL1-G1 mice by immunostaining ( Supplementary  Fig. 3a ) and western blotting (Supplementary Fig. 3b ). Furthermore, we performed structural analysis by PAS staining of mouse kidney sections and found no observable alterations in mice expressing risk alleles of APOL1 (Supplementary Fig. 3a ). Serum creatinine, BUN and urinary ACR measurements indicated no functional alterations in tubule-specific transgenic mice (Supplementary Fig. 3c ). Furthermore, transcript-level analysis for the kidney-injury markers KIM1 and COL4A (by real-time quantitative PCR (RT-qPCR)) showed no substantial differences among control mice and those expressing the G0, G1 or G2 alleles (Supplementary Fig. 3d ).
To further show that disease development in podocytes depends specifically on the presence of the risk variants, we identified mice with equal expression of the G0, G1 and G2 APOL1 variants and examined their phenotypes (Fig. 2a,b) . In mice with equal expression of G0, G1 or G2, those with G1 and G2 variants had significantly higher albuminuria, as indicated by a higher ACR level, when compared to those expressing the G0 reference allele (P = 0.0029 and 0.0061, respectively) (Fig. 2b) . Similarly, studies done in vitro show that G1 and G2 APOL1 variants expressed in transfected HEK293 cells at the same level as the G0 variant were associated with increased cytotoxicity as compared to transfected cells expressing the G0 variant (Fig. 2c) . These findings are recapitulated in human samples (Supplementary Table 4) . When glomerular expression of APOL1 was matched in low-and high-genetic-risk samples, high-risk samples had a significantly lower estimated glomerular filtration rate (eGFR) (P = 0.032) (Fig. 2d) . In summary, the phenotype in mice and humans, as well as cytotoxicity in vitro, is closely linked to the risk variants, which supports the notion that disease development is not a consequence of broad cytotoxicity.
Because APOL1-associated kidney disease follows complex-trait genetics, neither all humans nor all mice with a risk-associated genotype develop severe kidney disease. To understand the variation in disease severity, we first correlated APOL1 transcript levels with renal-function changes. We found a strong linear correlation between APOL1 transcript levels and albuminuria in mice with G1 and G2 podocyte-specific expression, whereas, we did not observe overt albuminuria in mice expressing the reference allele (Fig. 2e) . Similarly to albuminuria, histological damage was more severe in mice expressing higher levels of an APOL1 risk allele than in mice expressing the same risk allele at lower levels (Fig. 2f) . Furthermore, we inducibly expressed either a control vector or one expressing either G0, G1 or G2 in transfected HEK293 cells using the same doxycycline expression system that we used in vivo. We found that, under escalating doses of doxycycline, expression of G1 or G2 resulted in greater cytotoxicity when compared to cells expressing the G0 reference allele or a control vector, which suggests that G1 and G2 toxicity is dose dependent (Fig. 2g) .
To understand whether the renal-disease phenotype in patients also depends on APOL1 levels, we compared APOL1 transcript levels in glomeruli isolated from 286 human kidney samples. Patient characteristics are shown in Supplementary Table 4 . We found that APOL1 transcript level (regardless of genotype) was significantly higher in glomeruli isolated from CKD kidneys (GFR < 60) than in controls (GFR > 60) (P = 0.000283) (Fig. 2h) . This was true even when diabetic samples were excluded (Supplementary Fig. 4a) . Furthermore, we have also examined the correlation between glomerular APOL1 levels and GFR in low-and high-risk samples. APOL1 transcript levels are higher in lower GFR samples both in low-and high-risk samples (Supplementary Fig. 4b ). This relationship was much stronger in high-risk samples (Fig. 2d ) when compared to low-risk samples, just as we observed in our mouse model (Fig. 2e) .
Our studies also indicated that interferon is a strong regulator of APOL1 levels in both low-and high-risk human podocytes (Supplementary Fig. 4c ). We detected a strong, statistically significant correlation between STAT1 and APOL1 transcript levels in human glomeruli (P < 2.2 × 10 −16 ) (Supplementary Fig. 4d ) and found that STAT1 binds to APOL1 enhancers (Supplementary Fig. 4e ). 
a r t i c l e s
Given the strong correlation between APOL1 levels and phenotype development, we also examined whether turning APOL1 expression off in our mouse model would lessen disease severity. We placed mice on doxycycline-containing food for 14 d and either kept the mice on doxycycline or took them off the diet for 7 d (at day 21) or 17 d (at day 31). The decrease that we observed in albuminuria, as measured by Coomassie-stained gels of urine samples, when doxycycline treatment was halted indicates that albuminuria development is strongly correlated with expression of APOL1 risk alleles in podocytes (Fig. 2i) .
A role of APOL1 in autophagic flux Next, we studied the molecular mechanism of APOL1-variant-induced kidney disease. Immunogold electron micrographs of human kidney tissue samples showed that APOL1 localized to the plasma membrane-associated intracellular vesicles in podocytes (Fig. 3a) . We used intracellular-compartment-specific markers to determine APOL1 localization in cultured human podocytes. We identified colocalization of APOL1 with the early endosomal marker EEA1 and late endosomal marker RAB7 (Fig. 3b,c) . There was minimal colocalization with the recycling endosomal marker RAB11, the autophagic vacuole marker LC3, the lysosomal marker LAMP2 (Fig. 3b,c) , the Golgi marker GM130, the ER marker calnexin or the lipid-droplet marker perilipin 2 (Supplementary Fig. 5 ). Examination of GFP-APOL1 and RFP-RAB7 localization in transfected HEK293 cells further confirmed that APOL1 resides in the late endosomal compartment (Fig. 3d and  Supplementary Video 1) .
We noted that the expression of APOL1 in HEK293 cells using the TRE-APOL1 constructs (Supplementary Fig. 1 ) resulted in excessive accumulation of intracellular vesicles, which was more pronounced in the G1 and G2 variant cells than in the G0 controls ( Supplementary  Fig. 6a ). Immunofluorescence studies in human podocytes from low-risk (G0/G0) and high-risk (G1/G2)-allele subjects indicated an increase in RAB7 (late-endosome)-positive (Fig. 3e) and LC3II (autophagosomes)-positive (Fig. 3f) intracellular organelles in the high-risk-allele podocytes as compared to low-risk allele podocytes. Similarly, there was an increase in total RAB7, RAB11 and steadystate LC3II protein levels in transfected HEK293 cells expressing APOL1 risk allele as compared to those expressing the reference allele ( Supplementary Fig. 6b,c) . TEM of transfected cells expressing a risk allele indicated accumulation of different types of vesicle, including multivesicular bodies (MVBs, also called late endosomes) and autophagic compartments, as compared to reference-allele transfected cells (Fig. 3g-i) . Analysis of the morphometric characteristics of the autophagic vacuoles revealed a significantly higher abundance of autophagosomes (APGs or APs, double-membrane vesicles with content of similar characteristics to the surrounding cytosol) and a decrease in autolysosome number (AUT or ALs; single-membrane vacuoles with cargo in an advanced stage of degradation) in transfected cells expressing a high-risk allele as compared to that in G0 or control cells (Fig. 3h,i) . In addition, we noticed an expansion of vesicular compartments compatible with amphisomes (AMPs, resulting from the fusion of autophagosomes and MVBs; and containing cytosolic material as well as multiple small vesicles); the number of amphisome figures was even higher in cells transfected with APOL1 risk alleles as compared to those transfected with the reference allele (Fig. 3i) . Immunofluorescence and confocal spinning disk microscopy showed increased colocalization of APOL1 risk variants with late (RAB7 positive) and recycling (RAB11 positive) endocytic compartments in transfected HEK293 cells (Fig. 3j, Supplementary Fig. 6d,e  and Supplementary Videos 2,3) .
To further characterize the APOL1-induced intracellular-vesicle defect, we next examined autophagy, because there is dynamic interplay between autophagic and endocytic compartments under physiologic conditions. Furthermore, previous studies have proposed that APOL1 has a role in autophagy 21 . First, we quantified the extent of autophagic vacuoles in transfected HEK293 cells expressing the reference or risk alleles, as estimated by conjugated LC3 (LC3II) (Fig. 4a) . In agreement with the immunofluorescence and TEM data, we found that, at baseline, there was a greater amount of LC3II in cells expressing a risk allele as compared to cells expressing reference allele (Fig. 4a) .
Increased levels of LC3II can result from either increased autophagosome biogenesis or a blockage of autophagosome clearance. To distinguish between these possibilities, we examined autophagic vacuole content (amount of autophagic vesicles, represented by the LC3II level in baseline conditions) and autophagic flux (lysosomal fusion and degradation of autophagic cargo, represented by the degree of increase in LC3II after pharmacological blockage of lysosomal degradation) (Fig. 4b) . We speculated that the greater LC3II content associated with risk-allele (G1 or G2) expression was likely a consequence of lower autophagic flux (and reduced degradation of (Fig. 4b) . Analysis of TEM studies further confirmed that risk-allele-transfected cells contained a greater amount of autophagic vacuoles (APs), but fewer autolysosomes (ALs), as compared to cells transfected with the reference allele, indicating a blockage in autophagic flux (Figs. 3g and 4c) .
To examine the relevance of these findings to the human condition, we analyzed low-risk (G0/G0) and high-risk (G1/G2) human podocytes. These cells presented with a similar defect in autophagy; G1/G2 cells showed greater numbers of autophagic vacuoles at baseline, but defects in autophagic flux, as compared to G0/G0 cells (Fig. 4d,e) .
APOL1 variant is associated with the acidification of endocytic vesicles Next, we further analyzed the nature of the autophagic flux defect. A lysosomal defect would manifest as a defect in autolysosome formation (or reduced autophagic flux); therefore, we first analyzed lysosomes in control and risk-allele-expressing cells. LysoTracker analysis of reference and HEK293 cells transfected with APOL1 risk allele did not show substantial differences in lysosomal content or acidification (Supplementary Fig. 7a) . Identical results were seen in human podocytes harboring low-or high-risk alleles ( Supplementary  Fig. 7b) , which rules out a gross defect in lysosomal function.
The most likely explanation that would synthesize these results is that APOL1 risk variants interfere with lysosomal fusion with autophagosomes. We examined the colocalization of the lysosomal SNARE protein VAMP8 (ref. 22 ) with two autophagosome markers, Stx17 (Supplementary Fig. 7c,d ) and LC3II ( Supplementary  Fig. 7e,f) . We found a decrease in colocalization between VAMP8 and both Stx17 and LC3II in APOL1-G1 and APOL1-G2 transfected HeLa cells. These studies provide further evidence for a defect in autophagosome maturation.
Many cells respond to reduced fusion of autophagosomes with the lysosome by increasing the fusion of autophagosomes directly with the endosome (resulting in amphisomes). To further characterize the endocytic compartment in APOL1-transfected cells, we analyzed the uptake of fluorescently labeled, 10-kDa dextran in transfected HEK293 cells. In agreement with the TEM data, cells expressing APOL1 risk alleles displayed a significant increase (P < 0.05) in the amount of endocytic vesicles as compared to cells expressing the G0 reference allele (Supplementary Fig. 7g,h) . We also examined endosomal pH by using a 10-kDa dextran labeled with a pH-sensitive dye (pHrodo). This dye reaches acidic compartments by endocytosis, in contrast to LysoTracker, that freely permeates membranes to reach cellular acid compartments (Supplementary Fig. 7g) . We found that the acidification of the endosomes was defective in risk-alleletransfected HeLa cells (Supplementary Fig. 7i) , because the ratio of fluorescence between pHrodo and labeled dextran was lower in cells expressing APOL1 risk allele as compared to reference-alleletransfected HeLa cells. These studies indicate that, in the presence of APOL1 risk variants, there is a defect in autophagosome maturation, which likely results from diminished lysosomal fusion and impaired G2  G1  G0  G2  G1  G0  G2  G1 a r t i c l e s acidification of the late endocytic compartment, and thus probably leads to reduced autophagy flux. This defect in autophagy raises the possibility that the APOL1 risk variant is not degraded and therefore accumulates in cells. However, our experiments indicated that this was not the case, because APOL1 expression was generally slightly lower in risk-allele HEK293 cells than in reference-allele-transfected cells (Supplementary Fig. 7j ).
APOL1 variants result in inflammatory cell death (pyroptosis)
Podocyte loss resulting from cell death has a crucial role in the development of FSGS 23, 24 , a common histological manifestation of APOL1-associated kidney disease. Upon examining the mechanism of APOL1-induced cytotoxicity, we failed to observe any increase in apoptosis in transfected cells expressing an APOL1 risk variant (Fig. 5a) .
We therefore turned our attention to inflammatory-cell-death mechanisms because it has been shown that defects in noninflammatory cell death can shift toward inflammatory-cell-death pathways, including pyroptosis 25, 26 . We found that cleaved caspase 1, the key player in pyroptosis, was increased in APOL1-transfected cells. This was particularly pronounced in cells expressing the APOL1 risk alleles (Fig. 5b) . In pyroptosis, active caspase 1 cleaves interleukin (IL)-1β into a mature and active protein that eventually leaks out of the cell. We found that the level of mature IL-1β was increased in the medium of cells expressing APOL1 risk alleles as compared to reference-allele-transfected cells (Fig. 5b) .
To prove that pyroptosis contributes to APOL1-risk-allele-induced toxicity, we treated cells with the caspase-1-specific inhibitors Ac-YVAD-CHO and VX765, and found that APOL1-risk-allele-induced cytotoxicity was significantly reduced (Fig. 5c) . NLRP3 is a component of the inflammasome that activates caspase 1 during pyroptosis. CRID3 and parthenolide, as NLRP3 inhibitors, also reduced APOL1-risk-allele-induced cytotoxicity (Fig. 5d) . In line with our hypothesis that defective autophagy is the critical inducer of pyroptosis, we found that autophagy induces rapamycin (an mTOR inhibitor) 27 , and that STF66247 decreased APOL1-induced cytotoxicity (Fig. 5d) .
APOL1 risk alleles increase inflammatory cell death in mice
Because our in vitro data suggested inflammatory cell death in riskallele-expressing cells, we examined whether such a mechanism contributes to podocyte pathology in transgenic mice expressing an APOL1 risk allele. We found a marked reduction in podocyte number in risk-allele transgenic mice (Fig. 6a,b) and severe podocyte dedifferentiation indicated by decreased staining of nephrin in riskallele-expressing mice (Fig. 6a) . DNA fragmentation, as identified by TUNEL staining, was increased in APOL1-risk-allele-expressing mice (Fig. 6a,b) , indicating severe podocyte injury and death.
Next, we examined whether an autophagy defect similar to the one that we observed in vitro can be detected in vivo in mice expressing either the APOL1 reference or one of the risk alleles. TEM indicated a greater number of multivesicular bodies, amphisomes and autophagosomes in risk-allele-expressing mice than in mice expressing the G0 allele (Fig. 6c) . The AP-to-AL ratio was greater in mice expressing the APOL1 risk allele in podocytes than in those expressing the G0 allele (Fig. 6d) . Similarly to our in vitro finding, LC3II staining was greater in risk-allele-expressing mice than in G0-expressing mice (Fig. 6e) .
To further analyze the autophagy-defect-induced cell-death mechanism in vivo, we focused on pyroptosis, because we detected signs of greater inflammatory death in mice with podocyte-specific deletion of Atg7 (NPHS2-Cre;Atg7 flox/flox ), the gatekeeper of autophagy. IL-1β and NLRP3 expression was greater in Atg7-deleted mouse podocytes than in those of single transgenic controls (Supplementary Fig. 8) , which pointed toward a link between decreased autophagy and increased pyroptosis in vivo. In mice with podocyte-specific expression of APOL1, immunostaining for IL-1β, NLRP3 and caspase 1 showed greater protein expression in kidney sections of risk-allele-expressing transgenic mice than it did for those expressing the reference allele (Fig. 6f-h) , whereas we did not detect active caspase-3 activity in risk-allele-expressing mice (Fig. 6i) . RNA-seq-based unbiased analysis indicated that caspase 1, IL-1β and NLRP3 transcript levels were higher in mice expressing the risk allele when compared to referenceallele and control mice (Fig. 6j) . DISCUSSION G1 and G2 APOL1 variants have been strongly and reproducibly associated with kidney disease in patients. With the advent of whole-genome and whole-exome sequencing, hundreds of diseaseassociated variants have been identified, but animal-model experiments represent the mainstay of distinguishing causality from association in human genetics. Here we generated a mouse model with podocyte-specific inducible expression of APOL1 reference and risk variants. We show that risk variants recapitulate critical features of the human condition, which indicates that these variants are not only associated with disease, but also likely to cause renal pathology. Functional changes, such as albuminuria and azotemia, present in the risk-allele-expressing transgenic mice are consistently observed in patients. Structural changes in the mouse model included foot-process effacement and mostly solidified-type global sclerosis, with some segmental sclerosis and tubulointerstitial fibrosis. Although further studies in humans are needed, recent observations indicated that increased solidified-type global sclerosis and more severe tubulointerstitial fibrosis distinguishes individuals with high-risk APOL1 variants from individuals with low-risk genotypes 13, 14 . Our mouse-model studies here indicate that this lesion could represent an APOL1-specific phenotype that is superimposed on other CKD etiologies, such as hypertension, HIV or lupus (thus contributing to the seemingly variable phenotype of APOL1-induced kidney disease in humans). The APOL1 risk variant could act as a disease-accelerating mechanism by inducing global glomerulosclerosis. The phenotype development in the mouse model not only closely resembled the human condition, but was also cell-type and genotype restricted, indicating specific rather than nonspecific toxicity.
Our results also strongly indicate that phenotype development depends not only on the presence of G1 and G2 risk variants, but also on risk-variant expression levels. The correlation between APOL1 G1 or G2 levels and disease severity was also observed in human glomerular samples obtained from a large and diverse patient population. It is also in line with publications indicating that interferon (IFN) injection can lead to disease development in high-risk individuals 28 . Interferon seems to be a strong regulator of APOL1 expression, and in humans, STAT1 shows a remarkable correlation with APOL1 levels. We found that interferon increases cytotoxicity in high-risk cells, but that its effect is not additive to the transgenic overexpression of APOL1. We therefore suggest that the level of APOL1 G1 and G2 variants represents a 'second hit'; once risk-variant APOL1 levels rise above a critical threshold, disease develops ( Supplementary  Fig. 9 ). Environmental triggers, such as interferon treatment or infection, increase APOL1-risk-allele expression in kidney podocytes, which could contribute to disease progression. The recessive a r t i c l e s nature medicine VOLUME 23 | NUMBER 4 | APRIL 2017mode of inheritance is in line with the 'threshold' hypothesis, because heterozygous subjects have an average of 50% risk-variant levels-a level less likely to reach a critical threshold in geographical areas where the 'environmental trigger' is less strong. A recent publication indicates that in Sub-Saharan Africa, where both APOL1 risk variants and HIV incidence is much higher, even heterozygous individuals have a statistically significant increased disease risk 29 .
Recently a mouse model with podocyte-specific, noninducible expression of either G0 or G2-APOL1 was published 10 . The authors have described pre-eclampsia but no glomerulosclerosis in this model, which seems to be different from the human phenotype. In this model, APOL1 expression was significantly lower in mice with a risk-allele genotype. Given our results showing that the kidney phenotype is strongly associated with APOL1 levels, such a lower expression level might have played a part in the lack of observed renal disease. APOL1 expression in this model is constitutive, potentially causing a selective pressure and decreasing toxicity. Speaking to this issue in the pre-eclampsia model, the authors have obtained significantly fewer founders for mice with the risk allele than ones with the reference-allele genotype. The conditional, nducible-expression system that we used here likely circumvented such problems.
On a mechanistic level, APOL1 interferes with intracellular-vesicle trafficking by disrupting autophagosome maturation, which leads instead to expansion of mixed endocytic and autophagic compartments. The molecular mechanism whereby APOL1 affects autophagy and vesicular trafficking is not fully understood. We have found that the acidification of endocytic vesicles was altered in cells expressing one of the risk alleles. Although dissipation of acidic endosomal pH could be secondary to rerouting of autophagosomes toward fusion with endosomes instead of lysosomes, the most likely explanation for this defect is that APOL1 acts as an ion channel in vesicles. Acidification of vesicles occurs by the action of a vacuolar ATPase, an electrogenic process; therefore, an ion channel is needed to compensate for the electric changes. APOL1 has been shown to function as an ion channel in lipid bilayers 30 , and therefore, it is possible that it also functions as such in podocytes. Other possible mechanisms include a potential interaction of APOL1 with a GTPase or a SNARE protein, which would interfere with autophagosome maturation and lysosomal fusion. Future studies are needed to distinguish between these or other possibilities.
We show that the effect of APOL1 on endocytic and autophagic maturation results in lower autophagic flux in cells expressing one of the APOL1 risk alleles. It has been suggested that autophagy is induced by APOL1, given that it has a BH3 domain, and BH3-only proteins and BH3 mimetics induce autophagy through beclin 1 and the class III phosphorinositide-3-kinase complex 21, 31 . Additionally, both reference and risk variants of APOL1 increase LC3II levels, yet autophagic flux was not specifically investigated in these studies [32] [33] [34] . Although the induction of autophagosome formation could be in part responsible for the higher number of autophagosomes observed in cells expressing a APOL1 risk allele, our studies support the conclusion that most of the increase in steady-state levels of autophagosomes is due to reduced autophagic flux (lysosomal fusion and degradation of autophagic cargo). Podocytes, as do other terminally differentiated cells, such as neurons, have high basal autophagy rates, and autophagy is known to have an important role in podocyte homeostasis 35 . Defects in autophagy in podocytes have been shown to induce podocyte loss, focal segmental glomerulosclerosis and proteinuria [36] [37] [38] [39] .
Our results indicate that this defect in autophagy and endocytic trafficking is associated with inflammatory cell death. Caspase 1 and IL-1β have key roles in APOL1-induced cytotoxicity. These results offer new therapeutic possibilities for APOL1-associated kidney disease using already approved IL-1 inhibitors or other inflammatory-cell-death inhibitors 40, 41 . Given that caspase-1 knockout animals develop normally 42 , this pathway is potentially targetable.
Importantly, it seems that a positive-feedback regulatory loop exists between APOL1 and inflammatory pathways. Although APOL1 is part of the innate immune system and is strongly regulated by inflammatory cytokines, its expression results in inflammatory cell death 21 . Cytokines released after cell death can upregulate APOL1 levels, leading to further death. This regulatory loop likely explains the toxicity associated with APOL1 expression in vitro and in vivo. It might also explain the additive effect of HIV and the APOL1-risk-allele genotype on glomerulosclerosis development, in light of the cytokine-inducing effect of HIV and the potential additive activation of pyroptosis by the virus 43, 44 .
In summary, we show that expression of either APOL1 risk allele in podocytes causes lesions that recapitulate human APOL1-associated kidney disease at the functional, structural and molecular levels, thus proving that these variants are disease-causing mutations. Targeting these variants might reduce the increased kidney disease risk among millions of people of African descent.
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